3.58
1.13%
0.04
Dopo l'orario di chiusura:
3.47
-0.11
-3.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Maxcyte Inc Borsa (MXCT) Ultime notizie
MaxCyte to Participate in Two Upcoming Investor Conferences - StockTitan
MaxCyte to Join Key Investor Conferences in November - TipRanks
MaxCyte’s Insider Stock Activity in Focus - TipRanks
MaxCyte director Johnston sells $11,166 in stock - Investing.com
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - MarketBeat
Grant of Options and Restricted Stock Units - ShareCast
MaxCyte Awards Stock Options to Boost Growth - TipRanks
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
MaxCyte Appoints Cynthia Collins to its Board of Directors - ForexTV.com
MaxCyte Strengthens Board with Cynthia Collins Appointment - TipRanks
MaxCyte adds biotech veteran Collins to board - Investing.com
MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer - Head Topics
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - ForexTV.com
MaxCyte to Unveil Q3 2024 Financial Results - TipRanks
People on the Move: Ali Soleymannezhad, Chief Commercial Officer, MaxCyte - BioBuzz
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - citybiz
MaxCyte appoints new chief commercial officer - ShareCast
MaxCyte appoints Soleymannezhad as CCO - TipRanks
MaxCyte Names New CCO for Market Expansion - TipRanks
MaxCyte upgraded to Buy from Hold at Deutsche Bank - TipRanks
Marshall Wace LLP Acquires New Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha
Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock - MarketBeat
MaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in Stock - Defense World
MaxCyte Director Executes Stock Options Sale - TipRanks
MaxCyte director Stanley Erck sells shares worth over $178k - Investing.com
MaxCyte director Stanley Erck sells shares worth over $178k By Investing.com - Investing.com Australia
MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $80,161.97 in Stock - MarketBeat
Overcome the limitations of conventional transfection with MaxCyte Electroporation - LabRoots
MaxCyte Director Executes Stock Options and Sells Shares - TipRanks
MaxCyte Expands Share Capital, Fuels Cell Therapy Growth - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - Defense World
Maxcyte director Johnston sells shares worth over $11,000 By Investing.com - Investing.com Australia
Maxcyte director Johnston sells shares worth over $11,000 - Investing.com
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
MaxCyte (LON:MXCT) Stock Price Passes Below 50 Day Moving Average of $325.72 - MarketBeat
MaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $325.72 - Defense World
MaxCyte shares retain buy rating on strong cell therapy platform By Investing.com - Investing.com Australia
MaxCyte shares retain buy rating on strong cell therapy platform - Investing.com
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth - Yahoo Finance
Massachusetts Financial Services Co. MA Has $1.96 Million Stake in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases - MSN
Massachusetts Financial Services Co. MA Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BlackRock Ups Stake in MaxCyte to 9.75% - TipRanks
Rx Rundown: MaxCyte, Roche, and more - MM+M Online
MaxCyte Signs Strategic Platform License With Kamau Therapeutics To Accelerate the Development of Cell Therapies for Genetic Diseases - Technology Networks
Bank of New York Mellon Corp Has $1.66 Million Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte and Kamau Therapeutics sign platform license agreement - Pharmaceutical Technology
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):